Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Pharmaceutical Executive November 1, 2006 Sarah Houlton	Global Report: 'Bout Time The European Union has been late to enter the fight against counterfeiting. Fed up, Parliament has passed a proposal designed to give its countries the nudge they need.
The Motley Fool April 6, 2010 Brian Orelli	Kill It! Double-Teaming Malaria Malaria vaccine might not make Glaxo and Crucell rich, but the life-saving and PR benefits would be welcome.
Managed Care June 2003 Joyce Ochs, MBA	Bar Coding: Old Technology To the Rescue Grocery stores and the nonpharmaceutical parts of drug stores have been using bar codes for years. Now retail and hospital pharmacies will use the technology to save lives.
The Motley Fool February 25, 2010 Brian Orelli	An Untouched Market Waiting to Be Captured Unfilled prescriptions are a potential boon to drug companies.
Chemistry World July 3, 2006 Mark Peplow	Drug Screen Reveals Antimalarial Agent A widely-available antihistamine called astemizole could help in the battle against malaria, according to a survey of more than 2,600 drugs in a pharmaceutical library.
Chemistry World May 18, 2007 Hepeng Jia	China's Battle with Fake Drugs While China's pharmaceutical industry is experiencing rapid growth, a boom in counterfeit drugs is costing human lives and eroding the public's confidence in medical products.
The Motley Fool August 4, 2006 Selena Maranjian	Hooray for Big Pharma! There may actually be an upside to expensive pharmaceuticals. Invest in healthy, growing companies, and while you're forking over $100 for some pills, you may also be receiving $150 in dividends!
Managed Care October 2001 Patrick Mullen	Interview: Pharmacists in Need The executive vice president and CEO of the American Pharmaceutical Association says pharmacists are being inundated and need help...
The Motley Fool July 8, 2008 Brian Lawler	Blockbuster Drugs Bound for Extinction? One of the biggest classes of prescription drugs, those for diabetes treatments, faces tougher FDA standards.
BusinessWeek February 9, 2004 Charles Haddad	Fake Drugs, Real Disaster As operators get more canny, the FDA is cracking down on counterfeit medicine.
Chemistry World April 25, 2008 James Mitchell Crow	Drug Costs Cut on World Malaria Day Swiss pharmaceuticals firm Novartis has announced it will reduce by one fifth the price it charges governments and NGOs for artemisinin-based antimalarial Coartem.
Chemistry World January 29, 2008 Richard Van Noorden	Tiny Magnets to Repel Drug Counterfeiters A large pharmaceutical packaging company is hoping that nanotech security tags devised by a small Singaporean firm will help it combat counterfeit drugs.
The Motley Fool January 21, 2010 Brian Orelli	The Noble Gesture That Wasn't There may be a motive behind Glaxo helping to develop malaria treatments.
The Motley Fool June 30, 2009 Brian Orelli	A Cocktail for Drug Investors Drug cocktails aren't just for alchemists anymore. In many diseases they've become big business, and pharmaceutical investors would be smart to pay attention.
The Motley Fool January 8, 2008 Brian Orelli	Brits May Bludgeon Drug Companies The U.K.'s National Health Service delivers a shock to drugmakers; it is considering a 10% drop in the rate that it pays for drugs, to help it reach its goal of a 3% reduction in the nation's overall health-care bill.
The Motley Fool September 16, 2008 Brian Orelli	Is Pharma Still a Safe Investment? People still have to take their medicine. Health care, like food, is something that just isn't very discretionary. And that bodes well for drugmakers. Really.
The Motley Fool March 15, 2007 Brian Lawler	It's All Good for Drugmakers With the whole drug industry growing so strongly, those looking for a safe place to park their investing dollars would be smart to take a look at some of the largest generic drugmakers.
Chemistry World April 9, 2009 Phillip Broadwith	Dual-action malaria drug reverses resistance US chemists have designed a new class of antimalarial drug that can reverse the malaria parasite's resistance to existing drugs.
BusinessWeek August 5, 2010 Bennett & Randall	AIDS Drugs Flow to the Third World Drugmakers, once blasted for their practices, are slashing prices and licensing AIDS drugs for free to nonprofits or local manufacturers in developing countries.
Salon.com March 19, 2001 Ben Barber	Fighting the plague The World Trade Organization steps into Africa's AIDS crisis, creating incentives for pharmaceutical companies to give some of their drugs away.
Reason April 2001 Ronald Bailey	Goddamn the Pusher Man Why does everybody seem to hate the pharmaceutical industry?
Salon.com May 1, 2001 Daryl Lindsey	Amy and Goliath A first-year law student brought a giant pharmaceutical to its knees. But will her victory for South Africa's AIDS sufferers deprive the world of new medicines?
The Motley Fool May 7, 2010 Brian Orelli	Drug Companies: Recession-Resistant, but Government-Proof? Greece decided to take action and forced drugmakers to reduce drug costs by an average of 21.5%. Investors need to think twice before making the seemingly sure bet on pharmaceutical companies.
The Motley Fool December 12, 2007 Brian Lawler	Patent Bill Is No Panacea A new bill that was meant to strengthen the patent and other intellectual-property rights of drugmakers doesn't do enough to encourage pharma innovation.
Bio-IT World Dec 2005/Jan 2006 Salvatore Salamone	Gates, Clinton Address Global Health Summit The conference brought together leaders in business, government, medicine, public philanthropic groups, and the arts to address and develop solutions to the world's heath crises.
BusinessWeek October 18, 2004 Catherine Arnst	The Waning of the Blockbuster Drug What's promising now are drugs that target niche diseases. That means painful restructuring ahead for Big Pharma
The Motley Fool March 30, 2009 Brian Orelli	Change the Game? Change the Rules! There are ways for investors to get around Obama's plan to lower health care costs. Investing in drug companies in this time of "change" doesn't have to be scary. You've just got to find rule breaker-type drugmakers, because playing by the rules isn't going to cut it anymore.
Managed Care May 2007 Martin Sipkoff	Medication Therapy Management May Finally Enter the Mainstream Pharmacies can now take advantage of CPT codes to bill insurers for direct patient care. Will private payers follow Medicare in offering this service?
Bio-IT World November 14, 2003 John Dodge	Pfizer's Man with the R&D Plan As Pfizer senior vice president, science and technology, Peter B. Corr oversees $7.1 billion in annual research and development spending, the biggest private R&D budget in the world. In this interview, Corr talks about IT, clinical trials, and his $7-billion budget.
Chemistry World April 25, 2007 Richard Van Noorden	Malaria Drug Cures Mice with Single Dose U.S. chemists have adapted a Chinese herbal medicine to create a new generation of antimalarial drugs which could solve some of the current crop's failings.
Chemistry World April 25, 2013 Phillip Broadwith	Portable detector shines light on fake drugs The CD-3 counterfeit detection device uses a variety of different wavelengths of light to visually compare tablets, capsules and their packaging with genuine reference samples.
BusinessWeek September 5, 2005	Putting the FDA Out Front Deputy Commissioner Dr. Janet Woodcock explains how the agency has led the drive for personalized medicine.
Managed Care April 2004 John Carroll	$50M for Drug Comparisons Could Produce Valuable Results The Medicare amendment adopted late last year contains a provision that could help P&T committees, not to mention consumers, evaluate competing drugs.
Pharmaceutical Executive December 1, 2008 George Koroneos	Keeping It Real Between the push by the government for more online security and the addition of new anti-counterfeiting tools, pharma is making headway in the war against brand-jackers and counterfeiters. But it still has a way to go.
The Motley Fool August 26, 2010 Brian Orelli	Drug Prices Up, but Don't Read Too Much Into It AARP is out with its annual report on the cost of medications, and it's more of the same: bad news if you're a consumer, but good news if you're invested in drugmakers.
The Motley Fool November 30, 2010 Brian Orelli	A Witty Response to Pharma's R&D Dilemma According to GlaxoSmithKline CEO Andrew Witty, the pharmaceutical industry is a mess. That's the basic gist of his opinion piece in The Economist.
The Motley Fool December 11, 2006 Michael P. Cecil	Why Doesn't Buffett Buy Drug Companies? Investors, how do you estimate the amount of money that a drug company, or perhaps more simply one of its drugs, will produce over its lifetime?
InternetNews July 27, 2010	Oracle Debuts Drug-Tracking App for Big Pharma With its new Pedigree and Serialization Manager, Oracle is pitching an application to pharmaceutical companies that will enable them to track the movement of drugs across the supply chain.
The Motley Fool October 9, 2008 Brian Orelli	When Science, Marketing, and Investing Collide How a pharmaceutical tries to sell more drugs can provide clues about its management.
The Motley Fool August 6, 2007 Brian Orelli	Cheap Drugs on the Farm The House approves a prescription-drug import provision. Investors should keep an eye on the status of the bill, because laws that hurt the drugmakers' bottom lines will hurt their stock prices as well.
The Motley Fool October 8, 2007 Brian Orelli	New FDA Regulations for Drugmakers To deal with a growing backlog of pending applications, the FDA plans to stop its first-come, first-served system.
BusinessWeek February 7, 2005	Uniting Business to Fight Fakes Vivendi's Jean-Rene Fourtou, former International Chamber of Commerce head, talks about a new coordinated counteroffensive against counterfeiting.
BusinessWeek June 4, 2007 Eric Schine	Faking Out The Fakers Faced with a tidal wave of counterfeit goods, companies are turning to secretive sci-fi technology. But crooks catch on fast.
HHMI Bulletin Aug 2010 Robert Koenig	Collaborating Across an Ocean to Stop Malaria Two scholars, one from Mali and one from the United States team up to produce a vaccine for malaria.
The Motley Fool March 15, 2004 W.D. Crotty	60 Minutes on Drugs Will the weekly news magazine's prime-time slam rattle the drug stocks?
Chemistry World December 2009	Column: In the pipeline Is the pharmaceutical industry churning out copycat versions of existing therapies? The author dispels a few myths about 'me-too' drugs
The Motley Fool March 6, 2009 Brian Orelli	For Drug Companies, R&D Is Spelled C-R-O It seems likely that more and more pharma companies will try to get more bang for their bucks by spending them on research and development done outside the company, outsourcing it to clinical research organizations.
Managed Care May 2004 Thomas G. Dolan	Pharmacist Care An Idea Whose Time Is Still Coming For more than a decade, it has seemed this idea would catch fire. But many insurers are still looking for evidence that it can reduce overall costs.
Managed Care July 2005	Cost being equal, consumers prefer older drugs Seven out of 10 consumers would prefer a drug that had been on the market for 10 years or more, compared to a newer drug, even if the copayments were equal. This could be a sign that consumers are more inclined to start using generic medications.
Pharmaceutical Executive February 1, 2007 Joanna Breitstein	Net Effect Ripley Ballou may finally win approval for a vaccine he started testing as an army physician more than 25 years ago - an advance that could mark the beginning of a whole new phase in the battle against one of the world's great killers: malaria.